Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

ge healthcare technologies inc. - GEHC

GEHC

Close Chg Chg %
81.66 -1.65 -2.02%

Closed Market

80.01

-1.65 (2.02%)

Volume: 3.19M

Last Updated:

Mar 28, 2025, 4:00 PM EDT

Trade Now

Company Overview: ge healthcare technologies inc. - GEHC

GEHC Key Data

Open

$81.42

 Day Range

79.79 - 81.79

52 Week Range

74.51 - 94.80

 Market Cap

$37.34B

Shares Outstanding

457.30M

 Public Float

456.08M

Beta

1.32

 Rev. Per Employee

N/A

P/E Ratio

18.65

 EPS

$4.36

Yield

15.43%

 Dividend

$0.04

EX-DIVIDEND DATE

Jan 14, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

3.55M

  

GEHC Performance

1 Week
 
 -1.82%
 
1 Month
 
 -8.40%
 
3 Months
 
 2.34%
 
1 Year
 
 -11.99%
 
5 Years
 
 N/A
 

GEHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About ge healthcare technologies inc. - GEHC

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Advanced Visualization Solutions segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GEHC At a Glance

GE Healthcare Technologies, Inc.
500 West Monroe Street
Chicago, Illinois 60661
Phone 1-833-735-1139 Revenue 19.67B
Industry Medical Specialties Net Income 1.99B
Sector Health Technology 2024 Sales Growth 0.614%
Fiscal Year-end 12 / 2025 Employees 53,000
View SEC Filings

GEHC Valuation

P/E Current 18.655
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.005
Price to Sales Ratio 1.824
Price to Book Ratio 4.229
Price to Cash Flow Ratio 18.393
Enterprise Value to EBITDA 12.041
Enterprise Value to Sales 2.164
Total Debt to Enterprise Value 0.22

GEHC Efficiency

Revenue/Employee 371,169.811
Income Per Employee 37,603.774
Receivables Turnover 4.495
Total Asset Turnover 0.60

GEHC Liquidity

Current Ratio 0.996
Quick Ratio 0.793
Cash Ratio 0.303

GEHC Profitability

Gross Margin 41.45
Operating Margin 15.026
Pretax Margin 13.12
Net Margin 10.131
Return on Assets 6.082
Return on Equity 25.584
Return on Total Capital 11.182
Return on Invested Capital 12.423

GEHC Capital Structure

Total Debt to Total Equity 110.998
Total Debt to Total Capital 52.606
Total Debt to Total Assets 28.336
Long-Term Debt to Equity 91.855
Long-Term Debt to Total Capital 43.534
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ge Healthcare Technologies Inc. - GEHC

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
17.59B 18.34B 19.55B 19.67B
Sales Growth
+2.45% +4.30% +6.60% +0.61%
Cost of Goods Sold (COGS) incl D&A
10.41B 11.12B 11.60B 11.52B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
625.00M 633.00M 610.00M 580.00M
Depreciation
225.00M 228.00M 248.00M 268.00M
Amortization of Intangibles
400.00M 405.00M 362.00M 312.00M
COGS Growth
+0.13% +6.81% +4.28% -0.67%
Gross Income
7.17B 7.22B 7.96B 8.15B
Gross Income Growth
+6.01% +0.66% +10.18% +2.49%
Gross Profit Margin
+40.80% +39.37% +40.69% +41.45%
2021 2022 2023 2024 5-year trend
SG&A Expense
4.38B 4.66B 5.17B 5.20B
Research & Development
816.00M 1.03B 1.21B 1.31B
Other SG&A
3.56B 3.63B 3.96B 3.89B
SGA Growth
+8.20% +6.35% +10.97% +0.58%
Other Operating Expense
- - - -
-
Unusual Expense
(62.00M) (16.00M) 297.00M 310.00M
EBIT after Unusual Expense
2.86B 2.58B 2.49B 2.65B
Non Operating Income/Expense
58.00M 18.00M 448.00M 455.00M
Non-Operating Interest Income
- - 34.00M 26.00M
-
Equity in Earnings of Affiliates
27.00M 13.00M 11.00M 8.00M
Interest Expense
40.00M 86.00M 578.00M 520.00M
Interest Expense Growth
-39.39% +115.00% +572.09% -10.03%
Gross Interest Expense
40.00M 86.00M 578.00M 520.00M
Interest Capitalized
- - - -
-
Pretax Income
2.88B 2.51B 2.36B 2.58B
Pretax Income Growth
+6.09% -12.63% -6.01% +9.32%
Pretax Margin
+16.35% +13.70% +12.08% +13.12%
Income Tax
600.00M 563.00M 743.00M 531.00M
Income Tax - Current - Domestic
196.00M 493.00M 213.00M 70.00M
Income Tax - Current - Foreign
422.00M 324.00M 345.00M 412.00M
Income Tax - Deferred - Domestic
83.00M (261.00M) 82.00M 61.00M
Income Tax - Deferred - Foreign
(101.00M) 7.00M 103.00M (12.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
27.00M 13.00M 11.00M 8.00M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.27B 1.95B 1.62B 2.05B
Minority Interest Expense
46.00M 51.00M 46.00M 57.00M
Net Income
2.23B 1.90B 1.57B 1.99B
Net Income Growth
+11.06% -14.85% -17.18% +26.78%
Net Margin Growth
+12.68% +10.35% +8.04% +10.13%
Extraordinaries & Discontinued Operations
- - 18.00M (4.00M)
-
Discontinued Operations
- - 18.00M (4.00M)
-
Net Income After Extraordinaries
2.23B 1.92B 1.57B 1.99B
Preferred Dividends
- - - 183.00M
-
Net Income Available to Common
2.23B 1.92B 1.39B 1.99B
EPS (Basic)
4.902 4.221 3.044 4.3706
EPS (Basic) Growth
+11.06% -13.89% -27.88% +43.58%
Basic Shares Outstanding
454.71M 453.93M 455.00M 456.00M
EPS (Diluted)
4.902 4.221 3.024 4.3421
EPS (Diluted) Growth
+11.06% -13.89% -28.36% +43.59%
Diluted Shares Outstanding
454.71M 453.93M 458.00M 459.00M
EBITDA
3.42B 3.20B 3.40B 3.54B
EBITDA Growth
+2.09% -6.52% +6.29% +4.06%
EBITDA Margin
+19.45% +17.43% +17.38% +17.97%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 102.875
Number of Ratings 20 Current Quarters Estimate 0.914
FY Report Date 03 / 2025 Current Year's Estimate 4.709
Last Quarter’s Earnings 1.45 Median PE on CY Estimate N/A
Year Ago Earnings 4.49 Next Fiscal Year Estimate 5.254
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 13 17 17
Mean Estimate 0.91 1.09 4.71 5.25
High Estimates 0.93 1.17 4.82 5.53
Low Estimate 0.90 1.04 4.65 5.07
Coefficient of Variance 1.20 3.01 0.96 2.57

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 12 12
OVERWEIGHT 0 0 0
HOLD 6 7 6
UNDERWEIGHT 0 0 0
SELL 0 0 1
MEAN Overweight Overweight Overweight

Insider Actions for Ge Healthcare Technologies Inc. - GEHC

Date Name Shares Transaction Value
Mar 6, 2025 Frank R. Jimenez GC & Corporate Secretary 71,572 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 James K. Saccaro Chief Financial Officer 71,544 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 James K. Saccaro Chief Financial Officer 32,252 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Roland Rott CEO, Imaging 22,742 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Roland Rott CEO, Imaging 30,235 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Kenneth R. Stacherski Ch. Supply Chain & Serv. Ofc. 14,472 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Kenneth R. Stacherski Ch. Supply Chain & Serv. Ofc. 31,671 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 George Newcomb Chief Accounting Officer 3,307 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 George Newcomb Chief Accounting Officer 7,705 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 George Newcomb Chief Accounting Officer 6,549 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $87.35 per share 572,055.15
Mar 6, 2025 Frank R. Jimenez GC & Corporate Secretary 28,944 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Thomas J. Westrick CEO, Patient Care Solutions 9,096 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Adam Holton Chief People Officer 17,232 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Thomas J. Westrick CEO, Patient Care Solutions 15,320 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $87.35 per share 1,338,202.00
Mar 6, 2025 Thomas J. Westrick CEO, Patient Care Solutions 18,501 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Adam Holton Chief People Officer 12,404 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Philip D. Rackliffe CEO, AVS 17,473 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Philip D. Rackliffe CEO, AVS 14,058 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Kevin Michael Oneill CEO, PDx 13,231 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Peter J. Arduini President and CEO; Director 119,913 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Ge Healthcare Technologies Inc. in the News